Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Xian, Ying ^a   Wu, Jingjing ^a   O'Brien, Emily C ^a   Fonarow, Gregg C ^b   Olson, Daiwai M ^c   Schwamm, Lee H ^d   Bhatt, Deepak L ^e   Smith, Eric E ^f   Suter, Robert E ^g   Hannah, Deidre ^h   Lindholm, Brianna ^h   Maisch, Lesley ^h   Greiner, Melissa A ^a   Lytle, Barbara L ^a   Pencina, Michael J ^a   Peterson, Eric D ^a   Hernandez, Adrian F ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; COMPLICATION; FOLLOW UP; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84942311361     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h3786     Document Type: Article

References (39)

1. World Health Organization. Global burden of stroke. In: The atlas of heart disease and stroke. WHO, 2004 (available at www.who.int/cardiovascular-diseases/en/cvd-atlas-15-burden-stroke.pdf ua=1).
2. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
6. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
7. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
8. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
10. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
11. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
12. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22 179 patients with ischemic stroke. Stroke 2007;38:259-63.
13. Weimar C, Benemann J, Katsarava Z, et al. Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol 2008;60:142-8.
14. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236.
15. O'Brien EC, Xian Y, Fonarow GC, et al. Clinical commentary on "Certain uncertainty: life after stroke from the patient's perspective". Circ Cardiovasc Qual Outcomes 2014;7:970.
16. Hannah D, Lindholm B, Maisch L. Certain uncertainty: life after stroke from the patient's perspective. Circ Cardiovasc Qual Outcomes 2014;7:968-9.
17. Xian Y, O'Brien EC, Fonarow GC, et al. Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER): implementing the patient-driven research paradigm to aid decision making in stroke care. Am Heart J 2015;170:36-45.e11.
18. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2010;3:291-302.
19. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009;119:107-15.
20. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J 2012;163:392-8.e1.
21. Hammill BG, Hernandez AF, Peterson ED, et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009;157:995-1000.
22. Reeves MJ, Fonarow GC, Smith EE, et al. Representativeness of the Get With The Guidelines-Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. Stroke 2012;43:44-9.
23. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
24. Fonarow GC, Pan W, Saver JL, et al. Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA 2012;308:257-64.
25. Smith EE, Shobha N, Dai D, et al. Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With The Guidelines-Stroke Program. Circulation 2010;122:1496-504.
26. Quinn TJ, Dawson J, Lees JS, et al. Time spent at home poststroke: "home-time" a meaningful and robust outcome measure for stroke trials. Stroke 2008;39:231-3.
27. Elixhauser A, McCarthy EM. Clinical classifications for health policy research, version 2: Hospital inpatient statistics. Healthcare Cost and Utilization Project (HCUP 3) research note 1. Agency for Health Care Policy and Research, 1996. [AHCPR publication No 96-0017.]
28. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:2064-89.
29. Lichtman JH, Jones SB, Wang Y, et al. Outcomes after ischemic stroke for hospitals with and without Joint Commission-certified primary stroke centers. Neurology 2011;76:1976-82.
30. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010;19:596-603.
31. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
32. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probabilityweighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45:S103-7.
33. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
34. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
35. Bushnell CD, Zimmer LO, Pan W, et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol 2010;67:1456-63.
36. McAlister FA. The end of the risk-treatment paradox? A rising tide lifts all boats. J Am Coll Cardiol 2011;58:1766-7.
37. Bungard TJ, Ghali WA, McAlister FA, et al. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ 2001;165:301-2.
38. Mishra NK, Shuaib A, Lyden P, et al. Home time is extended in patients with ischemic stroke who receive thrombolytic therapy: a validation study of home time as an outcome measure. Stroke 2011;42:1046-50.
39. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64.